Practice

Study Confirms Safety and Efficacy of Adalimumab Biosimilar HS016 in IBD

November 21st 2023

By Cameron Santoro

A China-based study where data were collected from patients with inflammatory bowel disease (IBD) showed safety and efficacy of the adalimumab biosimilar HS016.

Study: Biosimilar Use, Dose Rounding Produce More Cost Savings Than Either Strategy Alone

November 18th 2023

By Deana Ferreri, PhD

A retrospective study of New England patients receiving trastuzumab or bevacizumab found that combining dose rounding and biosimilar use resulted in greater cost savings than either strategy alone.

Webinar: Where Do Biosimilars Fit Into the Cancer Treatment Puzzle?

November 16th 2023

In partnership with The Center for Biosimilars®, the International Generic and Biosimilar Association hosted a live webinar, where panelists gathered from around the globe to discuss benefits as well as major barriers and accessibility challenges associated with oncology biosimilars worldwide.

Part 3: Study Questions Usefulness of Clinical Efficacy Trials for Oncology Biosimilars in Europe

November 16th 2023

By Skylar Jeremias

In part 3 of a 3-part series for Global Biosimilars Week, The Center for Biosimilars® reviews an analysis investigating whether clinical efficacy studies have an impact on prescribing decisions for oncology biosimilars across Europe.

Panelists Deliberate Strategies to Enhance Biosimilar Integration in Managed Care Spaces

November 13th 2023

By Skylar Jeremias

At the recent Academy of Managed Care Pharmacy Nexus meeting, panelists discussed the impact of introducing biosimilars in new medical fields, emphasizing the need for more education and collaboration to ensure their smooth integration into health care systems.

Public Payer in Poland Saves €243 Million by Using Biosimilar TNF Inhibitors

November 11th 2023

By Skylar Jeremias

The use of biosimilars of tumor necrosis factor (TNF) inhibitors within Poland’s public payer saved over €243 million from 2013 to 2021, with about 68% of that coming from the rheumatic musculoskeletal diseases alone.

Physicians Agree on Safety of Biosimilars, Nonmedical Switching in IBD, Survey Says

November 2nd 2023

By Skylar Jeremias

An international survey found that providers agree that use of biosimilars in inflammatory bowel disease (IBD) is safe and effective in both patients who are treatment-naïve and those who are already being treated with a reference agent.

Dr Stephen Hanauer Gives Insight Into Growing US Adalimumab Market

October 29th 2023

By Skylar Jeremias

Stephen Hanauer, MD, professor of medicine, Feinberg School of Medicine, Northwestern University, reflects on data concerning the potential for adalimumab biosimilars to gain significant market share.

Commercial Biosimilar Coverage Is on the Rise, but Preferences Still Vary

October 28th 2023

By Skylar Jeremias

A poster from AMCP Nexus quantifies trends in biosimilar coverage within Tufts Medical Center, finding that payer coverage of these products has increased but individual preferences among payers still vary.

Report: Conflicting Guidelines, Rebate Walls Are Major Factors Determining Biosimilar Uptake

October 24th 2023

By Skylar Jeremias

Samsung Bioepis’ most recent biosimilar market report identified inconsistent medical guidelines, challenges with access and rebates, and acute vs chronic treatment duration as major factors influencing biosimilar uptake in the United States.